Developing next-generation macromolecule therapeutics

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.
The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity.
This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Science

The Challenge: Endolysosomal trapping of macromolecules

One of the greatest challenges for efficacy of macromolecule therapeutics that act on an intracellular level, is delivery into key cells. Macromolecule therapeutics nowadays rely on receptor-mediated endocytosis into the endosomal compartment. The endo-lysosomal membranes, however, prohibit efficient cytoplasmic access of such foreign substances. The therapeutic efficacy of such drugs is therefore highly dependent on endo-lysosomal vesicles degradation.
Cytosolic delivery of macromolecule therapeutics requires incredibly challenging technical optimizations or specialized drug delivery platforms. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem and exposes a significant need for the development of novel delivery mechanisms.

Our Approach: ENDOSCAPE®

At Sapreme, we are developing improved macromolecule delivery mechanisms by circumventing endosomal entrapment. Our ENDOSCAPE® platform is based on compounds which can release trapped cargo from the endo-lysosomal membranes, improving the therapeutic window and enabling access to intracellular targets with minimal toxicity.
By binding our technology to antibody-conjugated toxins and oligonucleotides, our goal is to enhance target engagement and improve therapeutic efficacy without limitation to biologic modality or indication.

News & Events

Press Releases:

October 7, 2021

Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the round follows promising 2020 and 2021 preclinical data demonstrating the effectiveness of Sapreme’s endosomal escape compound, SPT001. Read the full release here.

Events:

Upcoming events:
No upcoming events in the near future. Please check back soon.

 

Past events:
13 – 15 June | Boston, MA – 2nd Annual Oligonucleotides for CNS Summit

Miriam Bujny  (CDO) will be making an appearance at the 2nd Annual Oligonucleotides for CNS summit in Boston June 13-15. She will be delivering a talk on Efficient on-target delivery of oligonucleotides, showcasing in vitro and in vivo performance of Sapreme’s endosomal escape enhancers for various tissues and targets.

13 – 16 June | San Diego, CA – BIO International Convention 2022

In the week of 13 – 16 June, Sapreme will be represented at BIO 2022 in San Diego by Guy Hermans (CEO) and Henrik Luessen (Chief Business Officer). They are primed and ready to meet our current and future partners, explain our targeted, intracellular delivery technology and talk about how we might collaborate together towards truly innovative therapeutics. Do reach out should you find yourself here,  Guy Hermans and Henrik Luessen would be delighted to catch up.

13 – 16 June | San Diego, CA – BIO International Convention 2022

In the week of 13 – 16 June, Sapreme will be represented at BIO 2022 in San Diego by Guy Hermans (CEO) and Henrik Luessen (Chief Business Officer). They are primed and ready to meet our current and future partners, explain our targeted, intracellular delivery technology and talk about how we might collaborate together towards truly innovative therapeutics. Do reach out should you find yourself here,  Guy Hermans and Henrik Luessen would be delighted to catch up.

20 & 21 April | Boston, MA – 3rd Annual RNAi-based Therapeutics Summit

Guy Hermans (CEO) will be attending, and speaking at the 3rd Annual RNAi-Based Therapeutics Summit.  His presentation on “Efficient on-target delivery of oligonucleotides to the liver and beyond: in vitro performance of Sapreme’s endosomal escape enhancers” at the start of the first day is one not to miss!

25 – 27 April | Boston, MA   – Novel Format Conjugates Summit

Ruben Postel, founder and CSO, will be speaking in person on Tuesday 26th April at the Novel Format Conjugates Summit in Boston, MA. In his talk, he will discuss improved receptor-targeted cytoplasmic delivery of macromolecule payloads using Sapreme’s endosomal escape enhancers.

November 29-30, 2021

Sapreme’s Chief Development Officer Miriam Bujny will be speaking at the BioTech Pharma Summit 2021. The topic of her talk will be “Antibody-targeted cytoplasmic delivery of oligonucleotide- or protein conjugates using Sapreme’s endosomal escape enhancers”. She will be presenting data demonstrating how Sapreme’s SPT001 can deliver pharmaceutically relevant amounts of antibodies and antibody conjugates to the cytoplasm or nucleus in a tissue-specific manner, and provide perspective on ongoing developments.

September 23rd, 2021

Guy Hermans (CEO) will be speaking at the online SMI Oligonucleotide Therapeutics and Delivery Conference. In his spotlight session titled  “Targeted Cytoplasmic Delivery of Oligonucleotides”, he will present how Sapreme’s SPT001 compound enables intracellular delivery of non-membrane permeable biomolecules by enhancing their escape from the endosome. Furthermore, he will highlight recent proof-of-principle studies on nucleic acid delivery in vitro and in vivo, and provide perspective on ongoing developments.

September 26-29, 2021

Sapreme will be presenting novel validation data on its endosomal escape technology at the upcoming 17th Annual Meeting of the Oligonucleotide Therapeutics Society. In his short presentation “Efficient on-target delivery of oligonucleotides to the liver and beyond: in vivo performance of Sapreme’s endosomal escape enhancers”, Guy Hermans will showcase data highlighting in vivo gene knock-down in the liver at substantially reduced oligonucleotide doses through the use of SPT001 conjugation technology. Furthermore, results will be shared showing persistence of PD effects, and how tuning of coupling chemistry and SPT001 loading allow for further dose reductions.

About Sapreme:

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contacts: Guy Hermans, CEO +31 30 760 09 76 hermans@sapreme-technologies.com

For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher +49 89 238 877 30 sapreme@trophic.eu

Careers

Sapreme Technologies is a privately-owned biotech company developing a disruptive technology platform (ENDOSCAPE®) enabling the development of superior targeted therapeutics, such as antibody-drug conjugates and oligonucleotide-based drugs. We have seen rapid growth this year, and continue to recruit on a frequent basis. Please see our most recent opportunity listed here.

 

Principal Scientist – Antibody and Protein Science/Engineering (PS/E). We are currently  a principal scientist who will be taking on a key scientific and technology leadership role in the company. In this capacity, you will select and develop protein ligands and tools, driven by innovation and in-depth scientific insights, based on substantial experience in the drug discovery process of antibody and protein/peptide-based drugs. To this end, you will be developing a variety of protein reagents, such as antibodies, antibody fragments or non-antibody-based protein/peptide targeting ligands to enable targeted, intracellular delivery of protein-drug conjugates. The Principal Scientist will also contribute to the generation and characterization of intracellularly active therapeutic protein or peptide payloads, and fusion proteins or conjugates thereof for targeted intracellular delivery. In your role, you are responsible and accountable for multiple complex programs and projects that deliver high quality scientific results according to industry state-of-art. The role encompasses the planning and alignment of content and timelines with key stakeholders such as Senior Management, Project Management, outsourcing partners, and with your in-house peers such as the Principal Scientists for Chemistry/Conjugation and In vitro Biology, as well as the In vivo Evaluation Team. In our growing organization, you will initially report to the Chief Scientific Officer.

Click here to read the full job spec and apply. We welcome any questions you might have about this opportunity. Feel free to reach out to the hiring manager Ruben Postel, or submit your motivation and CV directly to: careers@sapreme-technologies.com

 

Open applications welcome

If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76

Address

Antonie van Leeuwenhoeklaan 9
USP Bilthoven A12-1
3721 MA Bilthoven
The Netherlands